Foundation Medicine Announces the Launch of FoundationOne®RNA Assay for Research and Investigational Use

FoundationOne®RNA offers additional molecular information through RNA sequencing and can preserve tissue through extraction of DNA and RNA from a single sample

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine Inc., today announced the launch of the research use and investigational use versions of FoundationOne®RNA, its broad tissue-based RNA test. While DNA sequencing with optimized targeting can detect most fusions, FoundationOne RNA can provide another layer of sophisticated fusion detection in 318 genes through RNA sequencing.

Foundation Medicine will be using an innovative extraction method where DNA and RNA can be isolated from a single Formalin-Fixed Paraffin-Embedded (FFPE) sample to minimize sample volume requirements and help researchers preserve limited tissue samples in clinical studies.

FoundationOne RNA for investigational use will be available for use in clinical trials and enables reporting of fusions across a subset of the 318 genes analyzed. The test will be especially valuable for studying non-small cell lung cancer, gastrointestinal cancers, and sarcomas.

FoundationOne RNA for research use will be available for exploratory use in analyzing 318 genes for fusion detection and has expanded capabilities to offer gene expression reporting of over 1,500 genes to support biomarker discovery.

“We are excited to offer our research partners additional, high-resolution molecular information that is complementary to the high-quality DNA sequencing we already provide,” says Troy Schurr, Chief Biopharma Business Officer at Foundation Medicine. “Foundation Medicine is always seeking new avenues to expand our research support offerings for our biopharma and discovery partners, and we look forward to exploring how this innovative test can open doors to more treatment options for cancer patients.”

Foundation Medicine is initially bringing FoundationOne RNA to market for research and investigational use and is developing the test for clinical use with an anticipated launch in 2024.

About Foundation Medicine: Your Essential Partner in Cancer Care
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn.

Foundation Medicine ^® and FoundationOne ^® are registered trademarks of Foundation Medicine, Inc.

Source: Foundation Medicine

Foundation Medicine:
Abigail Linehan, 781-534-3210
pr@foundationmedicine.com